Sun Pharma, CSIR-IICT ink licensing pact worth Rs 240 crore for patents

Sun Pharma will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totalling up to Rs 240 crore plus royalties on net sales from the commercialization of the products developed using these patents.

Mumbai: Sun Pharmaceutical Industries said on Wednesday that it has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology (CSIR-IICT) in Hyderabad for patents related to certain compounds.

These compounds have potential therapeutic activity across multiple indications in the pharma major's speciality focus areas. Under the terms of the license agreement, Sun Pharma gets an exclusive global license for the patents and any other future patents covered in the agreement.

Sun Pharma will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totalling up to Rs 240 crore plus royalties on net sales from the commercialization of the products developed using these patents. The pharma company will be responsible for the development, regulatory filings, manufacturing and commercialization of these potential products.

"This collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global speciality pipeline," said Managing Director Dilip Shanghvi.

Read Also: Sun Pharma records Total Revenue of Rs 8374.36 crore for June quarter

"CSIR-IICT is well-known for its high-quality research and we are proud to be associated with them. We are making earnest efforts to bring innovations from Indian research institutes to the market to address the unmet needs of patients globally. Our collaboration with CSIR-IICT is a step in this direction," he said in a statement.

This agreement will facilitate the addition of pre-clinical candidates to Sun Pharma's global speciality pipeline. A successful clinical development of these potential compounds may enable Sun Pharma to commercialize pharmaceutical products for various therapeutic indications over the long term.

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and India's top pharmaceutical company. It has 42 manufacturing facilities across six continents.

Read Also: Sun Pharma restructures senior management: Kal Sundaram, Kirti Ganorkar, Aalok Shanghvi get new responsibilities